Thermo Fishr Sci Stock Price, News & Analysis

OlivePoint Capital and Redwood Capital acquired 3900 Paramount Parkway, a 220,000-square-foot Class A office building in Research Triangle Park, Raleigh–Durham, on December 15, 2025. The property is 100% leased to Pharmaceutical Product Development (PPD), a subsidiary of Thermo Fisher Scientific (NYSE: TMO), backed by long lease duration and corporate credit support.

The buyers said they purchased the asset at a discount to replacement cost and at an attractive in-place yield, citing office-sector dislocation as a sourcing opportunity and RTP’s strong tenant demand driven by life sciences and tech.

Thermo Fisher Scientific (NYSE:TMO) announced on December 2, 2025 an expansion of its Bioprocess Design Center network across Asia with a new center in Hyderabad, India and enlarged centers in Incheon, Korea and Singapore. The tri-hub network aims to provide localized expertise, bench-to-pilot capabilities, single-use and hybrid systems, and collaborative spaces to accelerate process development, training and scale-up for biologics, vaccines and cell and gene therapies.

The company said the expansion supports faster, more cost-effective and more sustainable biomanufacturing across Asia and was developed in partnership with the Government of Telangana for the Hyderabad site.

Thermo Fisher (NYSE: TMO) priced a €2.1 billion offering of euro-denominated senior notes, expected to close on or about December 1, 2025. The issuance comprises €1.0B floating-rate notes due 2027 and €1.1B fixed-rate notes due 2035 with a 3.628% coupon. The notes are fully guaranteed by Thermo Fisher and will pay interest quarterly (floating) or annually (fixed). Net proceeds are for general corporate purposes, including acquisitions, debt repayment, working capital, capex, or share repurchases.

Thermo Fisher Scientific (NYSE: TMO) announced 510(k) clearance in the U.S. on November 12, 2025 for the EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay, an automated diagnostic platform to aid in the diagnosis of multiple myeloma and related disorders.

The EXENT System claims enhanced sensitivity for detecting and isotyping M‑proteins, automated workflows with up to six hours of walkaway time per shift, no prior mass spectrometry experience required, and recent authorization for sale in Canada; availability is listed for multiple countries.

Thermo Fisher Scientific (NYSE:TMO) announced that its Board of Directors has authorized the repurchase of $5 billion of its common stock in the open market or in negotiated transactions.

The authorization has no expiration date, letting the company repurchase shares over time subject to market conditions and internal decisions.

Thermo Fisher Scientific (NYSE: TMO) announced a quarterly cash dividend of $0.43 per common share. The dividend is payable on January 15, 2026 to shareholders of record as of December 15, 2025.

Thermo Fisher Scientific (NYSE: TMO) announced a definitive agreement to acquire Clario Holdings for $8.875 billion in cash plus potential earnouts and follow‑up payments.

Clario, with ~4,000 employees and expected $1.25 billion revenue in 2025, provides endpoint data solutions that supported ~70% of FDA drug approvals over the past decade. Thermo Fisher expects the deal to be immediately accretive to adjusted EPS by $0.45 in year one, to deliver ~$175M adjusted operating income from synergies by year five, and to grow the business at high single digits under Thermo Fisher ownership. Close is expected by mid‑2026, subject to approvals; funding will include debt financing and cash on hand.

Thermo Fisher Scientific (NYSE: TMO) reported Q3 2025 results for the quarter ended September 27, 2025. Revenue rose 5% to $11.12 billion with organic revenue growth of 3%. GAAP diluted EPS was $4.27 (in-line year‑over‑year) and adjusted EPS grew 10% to $5.79. Adjusted operating margin improved to 23.3% and adjusted operating income was $2.59 billion. The company completed acquisitions of a Filtration and Separation business and Sanofi’s Ridgefield sterile fill‑finish site, repurchased $1.0 billion of stock, launched several products, received an FDA approval for an Oncomine Dx test, and announced a strategic collaboration with OpenAI.

Thermo Fisher Scientific (NYSE: TMO) announced a strategic collaboration with OpenAI on October 16, 2025 to embed OpenAI APIs across product development, service delivery, customer engagement and operations.

Key initiatives include applying OpenAI to Thermo Fisher’s PPD clinical research business to shorten clinical trial cycle time, integrating AI into the Accelerator Drug Development solution across Phase I–III and manufacturing, and rolling out ChatGPT Enterprise to employees to build AI fluency.